Long‐Term Safety Profile of Ruxolitinib in Chronic Myeloproliferative Neoplasms: A Comprehensive Real‐World Analysis
Alberto Blanco Sánchez(Hospital Universitario 12 De Octubre), Joaquín Martínez‐López(Hospital Universitario 12 De Octubre), Gonzalo Carreño‐Tarragona, Rosa Ayala(Hospital Universitario 12 De Octubre), María Luisa Palacios‐Berraquero(Universidad Complutense de Madrid), Nieves López‐Muñoz, Rafael Colmenares(Hospital Universitario 12 De Octubre), Adolfo Sáez(Universidad Complutense de Madrid)
Cited by 3
Related Papers
Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma
|Blood|2014|429
Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels
|medRxiv|2020|234
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
|The Lancet|2023|194